Antibiotics - The Perfect Storm

We need new antibiotics to fight infections caused by resistant bacteria. But the marketplace, the structure of the pharmaceutical industry, regulatory agencies, and difficult science are conspiring to deny us the products we need. This blog will present perspectives and developments in the fight for new antibiotics.

Thursday, July 18, 2019

Expert Societies Need to Step Up

I have a modest proposal that comes from my recent discussions with Brad Spellberg, Lew Barrett and John Rex. I am grateful to all three of...

Tuesday, July 16, 2019

Q&A with Brad Spellberg - Another Point of View Part 2

You noted that a subscription payment system such as the one recently proposed by the UK for purchases of low-volume use antibiotics would ...

Q&A with Brad Spellberg - Another Point of View - Part 1

Dr. Spellberg is an old friend and a co-author of a recent paper (requires subscription or registration) from the New England Journal ...

Thursday, June 27, 2019

Musings on The Future of Antibiotic Biotech

Warning – this is a long one! Abbvie is buying Allergan – but not for its antibiotic franchise. They are more interested in Boto...

Monday, June 3, 2019

Antibiotics - Motivating Investors

I recently had a chat with Rick Bright. Rick is the Director, Biomedical Advanced Research and Development Authority (BARDA), Deputy Assis...

Monday, May 27, 2019

Antibiotic Research and Development - Public vs. Private Funding

Over the past decade, pull incentives as a solution to the broken antibiotic market have been proposed to entice companies into antibioti...

Innovation - response to comment

Google blogger no longer allows me to respond to comments in my own blog. I am obliged to respond, if needed, in a separate blog . . . ...

View web version

Powered by Blogger.